ArticleThrombosis research2009
Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease.
Article in Thrombosis research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Effects of simvastatin on tissue factor pathway of blood coagulation in STATCOPE (Simvastatin in the prevention of COPD exacerbations) trial.Journal of thrombosis and haemostasis : JTH · 2021Trial
- αIIbβ3-dependent platelet procoagulant activity promotes pulmonary arterial thrombosis triggered by circulating tissue factor.Thrombosis research · 2025Article
- Reducing Hospital Readmissions in Chronic Obstructive Pulmonary Disease Patients: Current Treatments and Preventive Strategies.Medicina (Kaunas, Lithuania) · 2025Review
- Biomarkers of Prothrombotic State and Risk Assessment of Exacerbations in Patients with Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2024Article
- Prognostic potential of neutrophil-to-lymphocyte ratio, platelet to lymphocyte ratio, and monocyte to lymphocyte ratio in acute myocardial infarction patients combined with chronic obstructive pulmonary disease.Frontiers in cardiovascular medicine · 2024Article
- The Complex Association between COPD and COVID-19.Journal of clinical medicine · 2023Review
- Pulmonary Embolism and Respiratory Deterioration in Chronic Cardiopulmonary Disease: A Narrative Review.Diagnostics (Basel, Switzerland) · 2023Review
- Review
- A critical evaluation of risk to reward ratio of quercetin supplementation for COVID-19 and associated comorbid conditions.Phytotherapy research : PTR · 2022Review
- Chronic obstructive pulmonary disease and COVID-19: interrelationships.Current opinion in pulmonary medicine · 2022Review
- Prothrombotic state in patients with stable COPD: an observational study.ERJ open research · 2021Article
- Hypercoagulable State in COPD-A Comprehensive Literature Review.Diagnostics (Basel, Switzerland) · 2021Review
- COVID-19 and COPD: a narrative review of the basic science and clinical outcomes.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Clinical relevance of chronic respiratory disease in Korean patients with pulmonary thromboembolism.Journal of thoracic disease · 2019Article
- Relationship between polycythemia and in-hospital mortality in chronic obstructive pulmonary disease patients with low-risk pulmonary embolism.Journal of thoracic disease · 2016Article
- Expression of tissue factor and forkhead box transcription factor O-1 in a rat model for chronic thromboembolic pulmonary hypertension.Journal of thrombosis and thrombolysis · 2016Article
- Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer.Clinical and translational medicine · 2015Article
- Managing comorbidities in COPD.International journal of chronic obstructive pulmonary disease · 2015Review
- Proinflammatory and prothrombotic status in emphysematous rats exposed to intermittent hypoxia.International journal of clinical and experimental pathology · 2015Article
- Impact of a functional polymorphism in the PAR-1 gene promoter in COPD and COPD exacerbations.American journal of physiology. Lung cellular and molecular physiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionChronic obstructive pulmonary disease (COPD) patients have increased risk for cardiovascular mortality and venous thromboembolism. Tissue factor (TF) is the physiological initiating mechanism for blood coagulation and is pro-inflammatory.
methodsWe have studied circulating blood-borne TF-procoagulant activity (TF-PCA), plasma coagulation factors (F) VIIa and FVIII, and thrombin-antithrombin (TAT) complexes in 11 stable, moderate-severe COPD patients, 10 free of exacerbation for >3 weeks.
resultsTF-PCA was increased in COPD patients (52.3+/-5.6 U/ml, (SE)) compared to control subjects (20.7+/-1.5, n=45, p<0.0001). TAT levels were increased (COPD patients: 2.99+/-0.65 ug/l; control subjects: 1.31+/-0.13, n=53, p<0.0001), indicating enhanced thrombin generation. Plasma FVIIa (the activated form of FVII) was higher in COPD (83+/-11 mU/ml; controls, 64+/-5 mU/ml, n=20) but did not reach statistical significance. Plasma FVIIc and FVIII were not increased. TF-PCA levels were inversely related to plasma FVIIa (r=-0.80, p=0.003) and FVIIc (r=-0.76, p=0.007).
conclusionsBlood-borne TF-PCA is elevated and constitutes a prothrombotic and proinflammatory state in stable but moderate-severe COPD, and may contribute to the increased risk for vascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.